BRIEF published on 02/04/2025 at 10:40, 1 year ago Valerio Therapeutics opts for strategic refocusing Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce un recentrage stratégique pour se concentrer sur le développement de médicaments early-stage et assurer une croissance durable. La société cherche un accord de financement à long terme Développement Financement Restructuration Médicaments Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year ago Inside Information / Other news releases Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
BRIEF published on 10/01/2024 at 00:56, 1 year 4 months ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 Résultats Financiers R&D Essai Clinique Valerio Therapeutics Anticorps À Domaine Unique
BRIEF published on 10/01/2024 at 00:56, 1 year 4 months ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
PRESS RELEASE published on 10/01/2024 at 00:51, 1 year 4 months ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
BRIEF published on 10/01/2024 at 00:45, 1 year 4 months ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
BRIEF published on 10/01/2024 at 00:45, 1 year 4 months ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 et ses mises à jour stratégiques Résultats Financiers Plateforme PlatONTM Acquisition D'Emglev Essai Clinique VIO-01 Innovations Thérapeutiques
PRESS RELEASE published on 10/01/2024 at 00:40, 1 year 4 months ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 year 4 months ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Published on 02/20/2026 at 18:30, 1 hour 42 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 27 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 5 hours 42 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 6 hours 4 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 6 hours 12 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 1 hour 36 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 hour 41 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 2 hours 12 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 12 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 18:00, 2 hours 12 minutes ago TERACT - Résiliation du contrat de liquidité
